Rheumatoid Arthritis Drugs Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 56.55 Billion |
| Market Size (2029) | USD 75.26 Billion |
| CAGR (2024 - 2029) | 5.88 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Rheumatoid Arthritis Drugs Market Analysis
The Rheumatoid Arthritis Drugs Market size is estimated at USD 56.55 billion in 2024, and is expected to reach USD 75.26 billion by 2029, growing at a CAGR of 5.88% during the forecast period (2024-2029).
The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, the rising prevalence of arthritis across the world, and the acceptance of biopharmaceuticals. Various factors, such as increasing age and lifestyle changes, are expected to raise the risk for rheumatoid arthritis, which is expected to drive the market growth over the study period. For instance, according to the data published by the National Center for Health Statistics in February 2024, the prevalence of arthritis was found to be directly proportional to the rising age across the world, rising from 3.6% in adults aged 18–34 to 53.9% in individuals aged 75 and older. This scenario may lead to increased adoption of therapies for rheumatoid arthritis treatment and thus drive the market’s growth.
The rising burden of rheumatoid arthritis in various age groups is expected to increase the need for its drug treatment, boosting the market growth. For instance, as per the data published by Statistique Canada in November 2023, the number of people aged 12 years and over in Canada with arthritis was reported to be 6.28 million in 2022, compared to 6.08 million in the previous year. Hence, the growing prevalence of arthritis among the population may increase the demand for arthritis drugs, which may drive the market growth over the forecast period.
Additionally, rising launches of biosimilars for treating rheumatoid arthritis may also contribute to market growth. For instance, in October 2023, Pfizer Inc. secured an interchangeable biosimilar designation for ABRILADA (adalimumab-afzb) from the US Food and Drug Administration (FDA). This interchangeable designation encompasses all approved indications of ABRILADA, which include specific patients with rheumatoid arthritis (RA). Similarly, in July 2023, Coherus BioSciences Inc. launched YUSIMRY (adalimumab-aqvh) for commercial sale in the United States. It is one of the biosimilars to Humira in treating rheumatoid arthritis. Hence, affordable rheumatoid arthritis treatments are anticipated to witness demand in the coming years.
Thus, owing to the abovementioned factors, such as the rising burden of rheumatoid arthritis and new product launches, the market is expected to grow over the forecast period. However, alternative treatment options and the expiration of the patents of branded drugs may hinder the market's growth during the forecast period.
Rheumatoid Arthritis Drugs Market Trends
The Non-steroidal Anti-inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Major Market Share During the Forecast Period
The NSAIDs segment is expected to hold a significant share of the rheumatoid arthritis drugs market during the forecast period. NSAIDs are widely utilized for the symptomatic treatment of rheumatic disorders. Disease-modifying anti-rheumatic drugs (DMARDs) are also considered the gold standard for treating moderate to severe rheumatoid arthritis. However, DMARDs are used to prevent rheumatoid arthritis from worsening. NSAIDs (non-steroidal anti-inflammatory medicines) are used to treat disease conditions like inflammation to offer symptomatic relief in patients.
The increasing prevalence of rheumatoid arthritis is boosting segment growth. With the growing number of arthritis cases, NSAIDs and their production are expected to observe healthy demand and supply throughout the forecast period. For instance, according to the data published by Monash University’s School of Public Health & Preventive Medicine in February 2024, over 5.3 million Australians are projected to be grappling with the pain and disability associated with arthritis by 2040. This translates to approximately 85,000 new cases emerging each year. Hence, the growing burden of arthritis, including rheumatoid arthritis, is expected to drive the usage of NSAIDs, as these are the first line of treatment for rheumatoid arthritis.
In March 2024, Endo International PLC and Par Pharmaceutical Inc. launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic counterpart to Amgen's (previously Horizon Therapeutics) DUEXIS. This combination medication not only alleviates symptoms of rheumatoid arthritis but also mitigates the risk of stomach and upper intestinal ulcers, a common side effect associated with the administration of ibuprofen alone. Thus, owing to the abovementioned factors, such as the growing burden of rheumatoid arthritis and new product launches, the NSAIDS segment is expected to grow further over the forecast period.
North America Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to hold a significant share of the rheumatoid arthritis drugs market and show the same trend over the forecast period. Factors such as the rising prevalence of rheumatoid arthritis, the strong foothold of key market players, the increasing launch of novel therapies such as monoclonal antibodies for rheumatoid arthritis, and rising investments from the market players for the development of novel treatments and biosimilars for this disease are expected to drive the market growth in the region.
The increasing prevalence of arthritis, particularly among older adults, underscores the urgent need for effective drug treatments. This trend is evident in recent statistics from both the United States and Canada. For instance, according to the Centers for Disease Control and Prevention (CDC), in February 2024, 18.9% of adults aged 18 and older were diagnosed with arthritis in 2022 in the United States. The prevalence was higher in women at 21.5%, compared to 16.1% in men. Similarly, according to data published by Statistique Canada in November 2023, the number of people aged 65 and older in 2022 was reported to be 3.17 million compared to 3.13 million in the previous year. Hence, the growing prevalence of arthritis, including rheumatoid arthritis, creates the need for drug treatment.
Furthermore, the new product launches in North America are expected to favor the widespread availability of drugs for rheumatoid arthritis, which is likely to boost the market growth in the region. For instance, in May 2024, Lupin Limited (Lupin), in collaboration with its partner Sandoz Canada (Sandoz), introduced the Rymti biosimilar in Canada. Rymti is approved for treating moderate to severe active rheumatoid arthritis, among other medical conditions. Therefore, owing to the abovementioned factors, such as a surge in arthritis cases and new product launches, the market in North America is expected to grow over the forecast period.
Rheumatoid Arthritis Drugs Industry Overview
The rheumatoid arthritis drugs market is semi-consolidated, and key players are manufacturing most rheumatoid arthritis drug products. The market leaders in this industry have established their position in the market. These manufacturers have a wide product range to offer and an extensive distribution system across the world. Additionally, emerging markets in Asia-Pacific are witnessing the entry of small players. Some major players in this market include AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, and Eli Lilly and Company.
Rheumatoid Arthritis Drugs Market Leaders
-
AbbVie Inc.
-
Amgen Inc.
-
Bayer AG
-
Boehringer Ingelheim GmbH
-
Bristol-Myers Squibb Company
*Disclaimer: Major Players sorted in no particular order
Rheumatoid Arthritis Drugs Market News
- June 2024: Celltrion unveiled its positive phase III results for CT-P47, a biosimilar targeting RoActemra, in patients grappling with moderate-to-severe rheumatoid arthritis (RA).
- April 2024: Kiniksa Pharmaceutical Ltd unveiled findings from Cohort 4 of its Phase 2 clinical trial for abiprubart, targeting rheumatoid arthritis. Abiprubart, an investigational humanized anti-CD40 monoclonal antibody, aims to block the interaction between CD40 and its ligand, CD154.
Rheumatoid Arthritis Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Preference Toward Development of Biologics and Biosimilars
4.2.2 Rising Burden of Arthritis
4.3 Market Restraints
4.3.1 Patent Expiration of Blockbuster Drugs
4.3.2 Alternative Treatment Options
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type of Molecule
5.1.1 Pharmaceuticals
5.1.2 Biopharmaceuticals
5.2 By Drug Class
5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.2 Disease-modifying Antirheumatic Drugs (DMARDs)
5.2.3 Corticosteroids
5.2.4 Analgesics
5.2.5 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over-the-Counter (OTC)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 Bayer AG
6.1.4 Boehringer Ingelheim GmbH
6.1.5 Bristol-Myers Squibb Company
6.1.6 Celgene Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Johnson & Johnson
6.1.9 Merck & Co. Inc.
6.1.10 Novartis AG
6.1.11 Lupin Limited
6.1.12 Alkem Laboratories
6.1.13 Regeneron Pharmaceuticals
6.1.14 Eli Lilly and Company
6.1.15 Pfizer Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Rheumatoid Arthritis Drugs Industry Segmentation
Rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the body's joints. It primarily affects the joints of the hands, wrists, elbows, knees, and ankles. It also affects the cardiac and respiratory systems and is a systemic disease. It thus exhibits symptoms of swelling, redness, and warmth in the affected areas. The drugs to treat rheumatoid arthritis include NSAIDs, corticosteroids, DMARDs, biologics, and analgesics, which help reduce inflammation, suppress the immune system, and relieve pain.
The rheumatoid arthritis drugs market is segmented by type of molecule, drug class, sales channel, and geography. By type of molecule, the market is segmented into pharmaceuticals and biopharmaceuticals. By drug class, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), corticosteroids, analgesics, and other drug classes. By sales channel, the market is segmented into prescription and over-the-counter (OTC). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers market sizes and forecasts in terms of value (USD) for the above segments.
| By Type of Molecule | |
| Pharmaceuticals | |
| Biopharmaceuticals |
| By Drug Class | |
| Non-steroidal Anti-inflammatory Drugs (NSAIDs) | |
| Disease-modifying Antirheumatic Drugs (DMARDs) | |
| Corticosteroids | |
| Analgesics | |
| Other Drug Classes |
| By Sales Channel | |
| Prescription | |
| Over-the-Counter (OTC) |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Rheumatoid Arthritis Drugs Market Research Faqs
How big is the Rheumatoid Arthritis Drugs Market?
The Rheumatoid Arthritis Drugs Market size is expected to reach USD 56.55 billion in 2024 and grow at a CAGR of 5.88% to reach USD 75.26 billion by 2029.
What is the current Rheumatoid Arthritis Drugs Market size?
In 2024, the Rheumatoid Arthritis Drugs Market size is expected to reach USD 56.55 billion.
Who are the key players in Rheumatoid Arthritis Drugs Market?
AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH and Bristol-Myers Squibb Company are the major companies operating in the Rheumatoid Arthritis Drugs Market.
Which is the fastest growing region in Rheumatoid Arthritis Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Rheumatoid Arthritis Drugs Market?
In 2024, the North America accounts for the largest market share in Rheumatoid Arthritis Drugs Market.
What years does this Rheumatoid Arthritis Drugs Market cover, and what was the market size in 2023?
In 2023, the Rheumatoid Arthritis Drugs Market size was estimated at USD 53.22 billion. The report covers the Rheumatoid Arthritis Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Rheumatoid Arthritis Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Rheumatoid Arthritis Drugs Industry Report
Statistics for the 2024 Rheumatoid Arthritis Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Rheumatoid Arthritis Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
